The FLOTILLA Study: Providing Continued Access to The Study Medicines Encorafenib and Binimetinib for Participants in Prior Clinical Trials
Sponsor: Pfizer
ClinicalTrials ID:NCT05203172
The FLOTILLA study is an open-label continuation trial for participants benefiting from encorafenib/binimetinib in prior studies. Eligible participants must have no severe adverse effects and agree to reproductive criteria. Interventions include various combinations of encorafenib, binimetinib, cetuximab, and ribociclib, administered at doses consistent with previous studies.
Patient Parameters
| Parameter | Options |
|---|
Program Overview
The purpose of this clinical trial (called the FLOTILLA study) is to give continued access to the study medicines, as well as safety follow-up, for participants in prior clinical trials of encorafenib and/or binimetinib.
All participants who took part in earlier encorafenib and/or binimetinib studies may participate the FLOTILLA study if they are still benefiting from the use of the study medicines. This will be determined by the study doctor. People may not participate in the FLOTILLA study if they have not enrolled in a prior study of encorafenib or binimetinib.
Participants that had enrolled but had stopped receiving the study treatment in a prior study cannot enrolled in this study. Participants in the FLOTILLA study will receive encorafenib and/or binimetinib at the same dose and frequency as in their prior study, for up to about 5 years.
Description
This is an open-label, continuation study for participants receiving study intervention(s) in an encorafenib/binimetinib Parent Study. The study is being conducted under a Master Protocol for Encorafenib/Binimetinib Continuation Sub-Studies with an individual encorafenib/binimetinib continuation sub-study protocol for each eligible Parent Study. Approximately 75 participants from potentially qualifying Parent Studies will be included in this Encorafenib/Binimetinib Continuation study.
This continuation study includes multiple sub-study protocols to allow participants from each of the following parent studies: C4211001 - NCT01320085; C4211003 - NCT01849874; C4221003 - NCT03864042; C4221005 - NCT01543698; C4221006 - NCT03911869; C4221009 - NCT02928224; C4221010 - NCT01436656; C4221013 - NCT02159066; ANCHOR-CRC - NCT03693170
Eligibility Criteria
Inclusion Criteria
- Any participant who is receiving study intervention and deriving clinical benefit (as determined by the principal investigator) in an encorafenib/binimetinib Parent Study, with no ongoing NCI CTCAE version 4.03 Grade ≥3 or intolerable Grade 2 AEs considered to be related to study treatment.
- Participants must agree to follow the reproductive criteria as outlined in the applicable Encorafenib/Binimetinib Continuation Sub-Study Protocol.
Exclusion Criteria
- Any medical reason that, in the opinion of the investigator or sponsor, precludes the participant from inclusion in the study.
Locations
| FACILITY | ZIP | CITY | STATE |
|---|---|---|---|
| St. Joseph's Hospital and Medical Center | 85004 | Phoenix | Arizona |
| St. Joseph's Hospital and Medical Center | 85013 | Phoenix | Arizona |
| Massachusetts General Hospital | 02114 | Boston | Massachusetts |
| HealthPartners Cancer Research Center | 55101 | Saint Paul | Minnesota |
| Regions Hospital Pharmacy | 55101 | Saint Paul | Minnesota |
| HealthPartners Specialty Center | 55130 | Saint Paul | Minnesota |
| MSK Basking Ridge | 07920 | Basking Ridge | New Jersey |
| Rockefeller Outpatient Pavilion (53rd Street) | 10022 | New York | New York |
| Memorial Sloan Kettering Cancer Center | 10065 | New York | New York |
Get This Program In Your Inbox
You can sign up and apply your patients for this program.